08:00 , Dec 19, 2011 |  BC Week In Review  |  Clinical News

ATx08-001: Phase II data

A double-blind, U.S. Phase II trial in 61 patients showed that twice-daily 2.5 and 7.5 mg oral ATx08-001 each met the primary endpoint of significantly reducing mean pain intensity scores from baseline to week 1...
07:00 , Sep 26, 2011 |  BC Week In Review  |  Company News

Aestus Therapeutics, ALS TDI deal

The partners added additional small molecules to their 2010 deal to evaluate compounds to treat amyotrophic lateral sclerosis (ALS). The expansion was based on positive data from preclinical studies. Aestus retains rights to all IP,...
07:00 , Sep 26, 2011 |  BC Week In Review  |  Company News

Aestus Therapeutics, Astellas deal

Astellas' Prosidion Ltd. subsidiary granted Aestus exclusive, worldwide rights to develop and commercialize ATx09-002 (formerly PSN357). Aestus plans to begin a Phase II trial of the glycogen phosphorylase inhibitor in post-herpetic neuralgia (PHN) by the...
00:58 , Sep 20, 2011 |  BC Extra  |  Company News

Prosidion, Aestus partner for pain compound

Prosidion Ltd. , a subsidiary of Astellas Pharma Inc. (Tokyo:4503), granted Aestus Therapeutics Inc. (North Brunswick, N.J.) exclusive, worldwide rights to develop and commercialize ATx09-002 (formerly PSN357). Aestus plans to begin a Phase II trial...
08:00 , Feb 28, 2011 |  BC Week In Review  |  Clinical News

ATx08-001: Phase II started

Aestus began a double-blind, placebo-controlled Phase II trial to evaluate low- and high-doses of oral ATx08-001 in about 60 patients. Aestus has exclusive, worldwide rights to ATx08-001 from Astellas (see BioCentury, July 5, 2010). Aestus...
07:00 , Jul 19, 2010 |  BC Week In Review  |  Company News

Aestus Therapeutics, Eisai deal

Aestus and Eisai's Eisai Inc. subsidiary partnered to develop therapeutics for psychiatric disorders. Aestus will identify existing compounds that have completed Phase I testing and conduct additional trials of the repurposed compounds. Eisai will provide...
07:00 , Jul 5, 2010 |  BC Week In Review  |  Company News

Aestus Therapeutics, Astellas deal

Astellas granted Aestus an exclusive, worldwide license to FK614 . Aestus, which renamed the compound ATx08-001 , plans to start a Phase II trial of the peroxisome proliferation activated receptor (PPAR) gamma agonist to treat...
07:00 , Mar 22, 2010 |  BC Week In Review  |  Company News

Aestus Therapeutics, ALS TDI deal

The partners will evaluate small molecules to treat amyotrophic lateral sclerosis. The institute will conduct preclinical work to evaluate compounds identified by Aestus using its biological data mining techniques. Further terms were not disclosed. Aestus...